CVLLY (CellaVision AB) 5-Year RORE % : -1.14% (As of Mar. 2026)


CVLLY CellaVision AB CVLLY
69 GF Score
Price $7.06
GF Value $12.48
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is CellaVision AB 5-Year RORE %?

CellaVision AB CVLLY +12.06% 69 5-Year RORE % is -1.14 as of Mar. 2026. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 703 Medical Devices & Instruments companies, CellaVision AB ranks better than 56.61% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. CellaVision AB's 5-Year RORE % for the quarter that ended in Mar. 2026 was -1.14%.

The industry rank for CellaVision AB's 5-Year RORE % or its related term are showing as below:

CVLLY's 5-Year RORE % is ranked better than
56.61% of 703 companies
in the Medical Devices & Instruments industry
Industry Median: -4.5 vs CVLLY: -1.14

CellaVision AB  (OTCPK:CVLLY) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


CellaVision AB 5-Year RORE % Related Terms


CellaVision AB 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for CellaVision AB's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellaVision AB 5-Year RORE % Chart

CellaVision AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.88 2.86 3.16 5.56 2.39

CellaVision AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.23 4.41 2.50 2.39 -1.14

CVLLY vs ABT, SYK, MDT: 5-Year RORE % Comparison

For the Medical Devices subindustry, CellaVision AB's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB 5-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where CellaVision AB's 5-Year RORE % falls into.


CVLLY
69GF Score
CellaVision AB CVLLY
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB 5-Year RORE % Calculation

CellaVision AB's 5-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.299-0.315 )/( 1.402-0 )
=-0.016/1.402
=-1.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -1.14 mean?
CellaVision AB (CVLLY) has a 5-Year RORE % of -1.14 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on CellaVision AB and its competitors. According to the industry distribution chart, CellaVision AB ranks #305 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 43.4%.
Is CellaVision AB's 5-Year RORE % too high?
CellaVision AB's current 5-Year RORE % is -1.14. Based on the distribution chart, CellaVision AB ranks #305 out of 703 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 5-Year RORE % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #305 out of 703 companies for 5-Year RORE %. This puts CellaVision AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Medical Devices & Instruments company?
A good 5-Year RORE % depends on the Medical Devices & Instruments industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on CellaVision AB and its competitors. CellaVision AB's current 5-Year RORE % is -1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current 5-Year RORE % is -1.14. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current 5-Year RORE % is -1.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CVLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48. GuruFocus considers CellaVision AB to be Significantly Undervalued.

Key valuation signals for CVLLY:

  • 5-Year RORE %: -1.14
  • GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
  • GF Score™: 69/100 with 1 warning sign

No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score

Get the complete analysis for CVLLY

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.06
Price
$12.48
GF Value